📰 News announcement! www.cancergrandchallenges.org/new-teams-an...
We’re thrilled to welcome five world-leading scientific teams, each awarded up to £20 million, to take on some of the toughest unanswered questions in #CancerResearch.
Find out more about the teams and their challenges.
L’Institut Imagine est signataire de l’Appel de Paris-Saclay, un collectif de plus de 25 acteurs d’excellence — universités, organismes de recherche et entreprises — réunis pour placer la science au cœur de la souveraineté européenne.
05.03.2026 09:02 — 👍 1 🔁 1 💬 0 📌 0
À l'occasion de la Journée internationale des maladies rares, l'Institut Imagine a organisé la projection du film « Qui brille au combat » de la réalisatrice Joséphine Japy — qui porte un regard sensible et puissant sur l'intimité d'une famille confrontée à la maladie.
28.02.2026 08:32 — 👍 2 🔁 1 💬 0 📌 0
📣 Call for young rare disease advocates! ERDERA is inviting young patients aged 12–21 to join the in‑person training in Paris on 23–25 April 2026. 🔗 Find out more and apply: https://loom.ly/yaURaLI
⏳ Application deadline: 8 March 2026 #ERDERA #RareDisease
Happening now! 🔬 Dr. Mickaël MENAGER (Institut Imagine, INSERM) is taking the stage to share insights from a decade of research.
Topic: "Lessons learned from almost 10 years of single-cell RNA-seq analyses in patients with autoimmune and autoinflammatory diseases." 🧪
↪️ Retour sur la web émission #MaladiesRares de Pharmaceutiques
Les intervenants ont analysé comment des pathologies touchant un très faible nombre de patients sont devenues un puissant moteur d’ #innovation pour l’ensemble du système de santé.
Pour en savoir plus : respifil.fr/actus/actual...
In this organoid model, no collagen IV trimer assembly is detected in the tubular or glomerular basement membranes—ASO treatment restored the defect.
@institutimagine.bsky.social
@upcite.bsky.social
Alport syndrome is a frequent cause of hereditary glomerulonephritis, and some pathogenic variants affect splicing.
Here, Hassan Saei @hassansaei.bsky.social & team establish a kidney organoid platform of AS & correct gene splicing using ASO therapy: doi.org/10.1172/jci....
Success! 🧪✨
BridgeBio confirms positive Ph3 results for infigratinib: the 1st oral therapy to improve growth in achondroplasia.
From Laurence Legeai-Mallet’s 2016 lab work to real impact today. 🧬
For more info: www.linkedin.com/posts/instit...
Rounding out the session is Tom Le Voyer from Institut Imagine.
He is discussing "NF-kB, Thymus and autoimmunity", exploring the critical signaling pathways that prevent our immune system from turning against itself. 📉🦠
That wraps up this week's talks! See you next week! 👏
Next on stage is Gonçalo Nogueira from @pasteur.fr
His talk, "Embryonic thymocyte-epithelial cell interaction plays an essential role in the establishment of adult T cell tolerance," highlights how early development shapes our immune system's future in the context of the thymus. 🧬🛡️
Now, a more detailed look at the ATO system within T-ALL! 🔍
Valentine Louis (INEM) and Clarisse Godard (Institut Saint-Louis) are presenting "Modeling human leukemia using a 3D ATO (Artificial Thymic Organoid) system."
🧪 We are kicking off this week’s MAGIC meeting! First up is @guillaumeandrieu.bsky.social from @inem-necker.bsky.social (Normal & Pathological Lymphoid Differentiation Lab).
He is presenting "Leukemia on ChIP: application," diving into new methodologies for understanding leukemia. 🔬 🧵👇
🧪 We are kicking off this week’s MAGIC meeting! First up is @guillaumeandrieu.bsky.social from @inem-necker.bsky.social (Normal & Pathological Lymphoid Differentiation Lab).
He is presenting "Leukemia on ChIP: application," diving into new methodologies for understanding leukemia. 🔬 🧵👇
It was great to visit the @institutimagine.bsky.social yesterday for a seminar on our work on cell-autonomous immunity in the #CNS 🧠🦠🧬 and interesting exchanges with many PIs & friends 😊
Today I got to visit & talk @institutpasteur.bsky.social (too busy for a pic!) 🥰 Fantastic 2 days! Thank you 🙏🏻
🚨Happy to share that our research on splice modulation therapy for X-linked Alport syndrome using organoid models has just been published!
I am grateful to all co-authors!
@institutimagine.bsky.social @insight.jci.org @gdorval.bsky.social @hkd-l.bsky.social
insight.jci.org/articles/vie...
Happening now at Institut Imagine! 🏛️✨
Prof. Anna Kajaste-Rudnitski (Univ. of Pavia) is on stage dissecting the "double-edged sword" of innate immunity. ⚔️🧬
She is explaining how the same mechanisms that protect us from viruses can block gene therapies and drive CNS inflammation.
Complete and partial forms of X-linked MCTS1 deficiency in patients with mycobacterial disease. New study by Qinhua Zhou (Fudan University), Jacinta Bustamante @institutimagine.bsky.social, Jonathan Bohlen @jonathanbohlen.bsky.social @lmumuenchen.bsky.social & colleagues rupress.org/jhi/article/...
06.02.2026 14:30 — 👍 6 🔁 4 💬 0 📌 0
A study from @casanovalab.bsky.social shows that autoantibodies in a small subset of the population can allow weakened vaccine viruses to escape control, explaining some adverse events tied to one kind of Chikungunya vaccine, which is no longer available in the U.S.
27.01.2026 20:24 — 👍 3 🔁 4 💬 0 📌 0
Jensen, @casanovalab.bsky.social, Mogensen @au.dk and colleagues study type I interferon neutralizing autoAbs in people with #HIV, and find that the prevalence does not significantly differ from that in the general population. rupress.org/jhi/article/...
@esidsociety.bsky.social
Wrapping up with Emmanuelle Six on Gene Therapy. 🧬
Chronic inflammation "exhausts" our blood stem cells (HSPCs), making them less fit for genetic engineering. Emmanuelle is sharing solutions to protect stem cell fitness, ensuring that life-saving gene therapies work better and last longer. 🧪
Thiago Trovati is discussing a creative approach to Sickle Cell Disease (SCD): drug repurposing. 🔄
Focusing on Acute Chest Syndrome (a life-threatening complication), he’s exploring how drugs like tocilizumab, might help SCD patients by addressing ineffective erythropoiesis.🩸 #Hematology #SCD
Deep dive into the gut with David Skurnik (INEM). He has identified Oxalyl-CoA decarboxylase as a critical "survival tool" for Adherent Invasive E. coli (AIEC) in the harsh, acidic environment of the inflamed gut. 🦠
05.02.2026 12:32 — 👍 3 🔁 1 💬 1 📌 0
Next, Marie Louise Frémond talking about interferonopathies. These rare genetic disorders are driven by an "overdose" of type I interferon.
She's highlighting the efficacy of Anifrolumab—an IFNAR1 receptor blocker. Results show a significant "normalization" of the interferon signature in patients. 💊
📢 Kicking off today’s MAGIC meeting: Jean-François Gautier (Lariboisière) is discussing the shift in how we view Type 2 Diabetes, not just as a metabolic disorder, but as a chronic inflammatory disease. 🧬
05.02.2026 12:04 — 👍 6 🔁 2 💬 1 📌 0
🧬 Advancing Research in Paris with the Region's First AVITI24™ (Element Biosciences) !
We are thrilled to announce that Institut Imagine has officially acquired the first AVITI24 system in Paris.
Live at our weekly seminar: Prof. Chantal Pichon (Univ. Orléans) on the design of imidazolium lipid-based LNPs for mRNA delivery. 🧬
These LNPs use pH-responsive headgroups to improve cytosolic release for cancer vaccines & immune cell engineering. The future of nanomedicine! 🧪🎯 #mRNA #LNP
X-linked MCTS1 deficiency causes susceptibility to mycobacterial disease. In @jhumimmunity.org, Zhou et al. show that report 4 new patients carrying 3 previously undescribed truncating or loss-of-expression variants, presenting w/ BCG disease or M. abscessus infection. rupress.org/jhi/article/...
30.01.2026 18:00 — 👍 2 🔁 2 💬 1 📌 0
X-linked MCTS1 deficiency causes susceptibility to mycobacterial disease. Zhou, Bustamante, Bohlen et al. show that report 4 new patients carrying 3 previously undescribed truncating or loss-of-expression variants, presenting w/ BCG disease or M. abscessus infection. rupress.org/jhi/article/...
30.01.2026 17:00 — 👍 5 🔁 4 💬 1 📌 0
1/ We are excited to share our new report in PNAS: all three cases of encephalitis triggered by the live-attenuated chikungunya (CHIKV) vaccine (IXCHIQ®) are due to pre-existing autoantibodies neutralizing type I IFN (AAN-I-IFN) (doi.org/10.1073/pnas...).
26.01.2026 21:29 — 👍 37 🔁 12 💬 1 📌 3